Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Sickle Cell Disease
source: Nature Reviews Disease Primers
authors: Gregory J. Kato, Frédéric B. Piel, Clarice D. Reid, Marilyn H. Gaston, Kwaku Ohene-Frempong, Lakshmanan Krishnamurti, Wally R. Smith, Julie A. Panepinto, David J. Weatherall, Fernando F. Costa & Elliott P. Vichinskysummary/abstract:
Sickle cell disease (SCD) is a group of inherited disorders caused by mutations in HBB, which encodes haemoglobin subunit β. The incidence is estimated to be between 300,000 and 400,000 neonates globally each year, the majority in sub-Saharan Africa. Haemoglobin molecules that include mutant sickle β-globin subunits can polymerize; erythrocytes that contain mostly haemoglobin polymers assume a sickled form and are prone to haemolysis. Other pathophysiological mechanisms that contribute to the SCD phenotype are vaso-occlusion and activation of the immune system. SCD is characterized by a remarkable phenotypic complexity.
Common acute complications are acute pain events, acute chest syndrome and stroke; chronic complications (including chronic kidney disease) can damage all organs. Hydroxycarbamide, blood transfusions and haematopoietic stem cell transplantation can reduce the severity of the disease. Early diagnosis is crucial to improve survival, and universal newborn screening programmes have been implemented in some countries but are challenging in low-income, high-burden settings.organization: University of Pittsburgh, USA; Imperial College London, UK; National Heart, Lung and Blood Institute, USA; The Gaston and Porter Health Improvement Center, USA; Sickle Cell Foundation of Ghana, Ghana; Emory University School of Medicine, USA; Virginia Commonwealth University, USA; Medical College of Wisconsin and Children's Hospital of Wisconsin, USA; John Radcliffe Hospital, UK; University of Campinas - UNICAMP, Brazil; University of California, USA
Safety and early hints of benefit seen in phase 1b trial of PF-04447943Sickle cell disease (SCD) patients were ...
Hydroxyurea Treatment for Sickle Cell DiseaseHydroxyurea is a medicine that can help ...
HABIT Efficacy and Sustainability Trial, a Multi-Center Randomized Controlled Trial to Improve Hydroxyurea Adherence...Background: Hydroxyurea (HU) is recomme...
Hydroxyurea improves lung function in children with sickle cell diseaseFor the first time, researchers were abl...
Sickle cell patient with severe anemia rapidly improves with voxelotor, case study showsGlobal Blood Therapeutics (GBT) reported...
More Curative Bone Marrow Transplants are Successful When Patients Given Double the Radiation Beforehand, Study SaysThe success rate of bone marrow transpla...
MaxCyte, Inc. to Present Positive Preclinical Data for Sickle Cell DiseaseMaxCyte, a US-based global company dedic...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.